Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation

The atypical chemokine receptor 3 (ACKR3), formerly known as CXC-chemokine receptor 7 (CXCR7), has been postulated to regulate platelet function and thrombus formation. Herein, we report the discovery and development of first-in-class ACKR3 agonists, which demonstrated superagonistic properties with Emax values of up to 160% compared to the endogenous reference ligand CXCL12 in a fi-arrestin recruitment assay. Initial in silico screening using an ACKR3 homology model identified two hits, C10 (EC50 19.1 mu M) and C11 (EC50 = 11.4 mu M). Based on these hits, extensive structure-activity relationship studies were conducted by synthesis and testing of derivatives. It resulted in the identification of the novel thiadiazolopyrimidinonebased compounds 26 (LN5972, EC50 = 3.4 mu M) and 27 (LN6023, EC50 = 3.5 mu M). These compounds are selective for ACKR3 versus CXCR4 and show metabolic stability. In a platelet degranulation assay, these agonists effectively reduced P-selectin expression by up to 97%, suggesting potential candidates for the treatment of platelet-mediated thrombosis.

Automated summary

This study reports the discovery and development of first-in-class ACKR3 agonists, which demonstrated superagonistic properties in a fi-arrestin recruitment assay. Through structure-activity relationship studies, novel compounds with selective activity against ACKR3 were identified, showing potential as candidates for the treatment of platelet-mediated thrombosis.